GW-501515 (Cardarine)

Endurance and Fat Loss Support

Zionova’s GW-501515 offers US men a reliable solution for improving endurance, boosting fat loss, and achieving a lean physique. As a PPAR-delta receptor agonist, Cardarine enhances cardiovascular performance and fat metabolism, making it a top choice for conditioning and cutting cycles.

Why Choose Zionova’s GW-501515?

Zionova is trusted by athletes for high-quality performance enhancers. GW-501515 Cardarine provides effective and consistent results, helping users achieve their fitness goals without hormonal side effects.

Product Details

• Product Name: GW-501515 Cardarine
• Tablets per Bottle: 50
• Dosage per Tablet: 5mg

Tailor your intake to match your training intensity and goals with these precise doses.

Medical Uses

GW 501516, also known as GW1516 or Cardarine, is an experimental compound that activates the peroxisome proliferator activated receptor delta. It is not an FDA approved human medicine and has no FDA approved medical indication.

The FDA identifies GW 501516 and Cardarine as names for the same chemical substance. The FDA also states that inclusion of a substance in its database does not mean that the substance has received regulatory approval.

GW 501516 has been investigated in scientific research involving metabolic and cardiovascular processes. Investigational research should not be confused with an approved medical treatment.

There are therefore no established FDA approved medical uses for a product marketed as Zionova GW 501516 Cardarine. Explore GW-501515 Zionova USA

U.S. Safety Information

GW 501516 has not been approved by the FDA for human medical use. The FDA has previously identified GW 501516 products marketed for human use as unapproved new drugs.

A major concern surrounding GW 501516 is its experimental safety profile. Development of the compound was discontinued after concerning findings in long term animal research. These findings contributed to the compound not becoming an approved human medicine.

The FDA explains that unapproved drugs have not undergone the product specific review necessary to establish their safety, effectiveness, quality, purity, manufacturing consistency, and accurate labeling.

The commercial name Zionova does not establish FDA approval or demonstrate that a particular product has been evaluated for safety, effectiveness, composition, or manufacturing quality. Explore GW-501515 Zionova USA

FAQs

What is GW 501516

GW 501516 is an experimental compound that activates PPAR delta. It is also known as GW1516, GW501516, and Cardarine.

Is GW 501516 FDA approved

No. GW 501516 is not an FDA approved human medicine.

Does GW 501516 have approved medical uses

No. There are currently no FDA approved medical indications for GW 501516.

Is GW 501516 a steroid

No. GW 501516 is not an anabolic steroid and is not a SARM. It is a PPAR delta agonist and is classified as a metabolic modulator.

Is Zionova Cardarine FDA approved

The Zionova brand name does not establish FDA approval. Approval applies to a specific drug product that has undergone the required regulatory evaluation.

Is GW 501516 considered a dietary supplement in the United States

No. The FDA has treated products containing GW 501516 that were marketed for human use as unapproved drugs rather than approved dietary supplements.

Is GW 501516 prohibited in sports

Yes. The World Anti Doping Agency lists GW 1516 and GW 501516 among prohibited PPAR delta agonists.

Why is GW 501516 considered experimental

GW 501516 was investigated as a potential therapeutic compound but did not become an approved human medicine. Important safety concerns emerged during its development, so it should not be presented as an established treatment.

Conclusion

GW 501516, also known as GW1516 or Cardarine, is an experimental PPAR delta agonist and not an FDA approved human medicine.

It has no FDA approved medical indication, and products marketed under names such as Zionova should not be assumed to have undergone FDA evaluation for safety, effectiveness, quality, or manufacturing consistency.

Its experimental status and significant safety concerns mean that it should not be presented as an established treatment or dietary supplement. Explore GW-501515 Zionova USA